The future of the global mesenchymal stem cells market looks promising with opportunities in the disease modelling, drug development & discovery, stem cell banking, tissue engineering, and toxicology study markets. The global mesenchymal stem cell market is expected to reach an estimated $6.6 billion by 2030 with a CAGR of 13.1% from 2024 to 2030. The major drivers for this market are rising incidence of chronic conditions including diabetes, cancer, and autoimmune illnesses, growing appeal of regenerative medicine, and surge in research and development efforts by biopharmaceutical firms to create innovative therapies utilizing mesenchymal stem cells.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the mesenchymal stem cell
market by workflow (cell sourcing & isolation, culture &
cryopreservation, differentiation, and characterization), type (autologous and
allogeneic), application (disease modelling, drug development & discovery,
stem cell banking, tissue engineering, toxicology studies, and others), and
region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market,
autologous and allogeneic are the major segments of mesenchymal stem cell
market by type. Lucintel forecasts that allogeneic will remain the larger
segment over the forecast period due to strong safety track record of
allogeneic mesenchymal stem cells in clinical use is noteworthy, and
transplantation of allogeneic MSCs is poised to become a groundbreaking
cell-based therapeutic method owing to its low potential for triggering immune
responses and its immunosuppressive properties.
Within this market,
disease modelling will remain the largest segment over the forecast period due
to the utilization of cellular illness models in conjunction with
patient-specific MSCs provides an excellent tool for pathological research.
North America will
remain the largest region over the forecast period because the significant
volume of clinical trials is currently in progress within the United States,
aimed at evaluating the effectiveness and safety of mesenchymal stem cells as a
potential treatment option for various life-threatening diseases.
Thermo Fisher
Scientific, Cell Applications, Axol Biosciences, Cytori Therapeutics, STEMCELL
Technologies, Cyagen Biosciences, Celprogen, Brainstorm Cell, Stemedica Cell
Technologies, and Merck are the major suppliers in the mesenchymal stem cell
market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment